| Company type | Private |
|---|---|
| Industry | |
| Founded | 2019 |
| Founder |
|
| Headquarters | , Australia |
Area served | |
| Products |
|
| Brands |
|
| Website | https://www.eucalyptus.health/ |
Eucalyptus Health is an Australian digital health company founded in 2019 that operates telehealth services including Pilot (men's health), Juniper (weight management), Software (dermatology), and Kin (reproductive health). [1] [2] The company is headquartered in Sydney and has expanded to the United Kingdom, Germany, and Japan. [3]
Eucalyptus was founded in 2019 by Tim Doyle, Charlie Gearside, Benny Kleist, and Alexey Mitko. [1] The company launched Pilot, a men's health telehealth service, as its first brand. [4] Subsequent brands included Juniper (weight management), Software (dermatology), and Kin (fertility and reproductive health). [2]
In June 2023, Eucalyptus acquired the digital assets of Jenny Craig Australia after the brand entered voluntary administration. [5]
The company raised AUD $8 million in Series A funding in May 2020, $30 million in Series B in July 2021, and $60 million in Series C in January 2022. [6] [7] A 2023 funding round raised an additional AUD $50 million. [8] The company was valued at $560 million in April 2023. [9]
Eucalyptus provides telehealth consultations, e-prescriptions, and medication delivery through partner pharmacies. [2] Services are delivered through specialized brands targeting specific health concerns:
The company reported revenue of AUD $120.9 million in FY 2024, with 60% generated from international markets. [2]
The Royal Australian College of General Practitioners (RACGP) raised concerns in 2023 about telehealth services using remote questionnaires to prescribe GLP-1 receptor agonists, questioning whether such methods provided adequate clinical assessment. [14] The Therapeutic Goods Administration (TGA) warned telehealth companies against advertising prescription-only medicines directly to consumers. [15]
During GLP-1 medication shortages in 2023-2024, Eucalyptus partnered with compounding pharmacies to provide compounded semaglutide. This practice drew criticism from pharmaceutical manufacturers and regulators. [16] [17] The Australian federal government subsequently banned pharmacy compounding of GLP-1 drugs from October 2024. [15]
Media reports in The Sydney Morning Herald and The Australian questioned whether social media and influencer campaigns for Eucalyptus brands overstated treatment results. [12] [15] ABC's Media Watch raised concerns about whether television segments promoting the company's services blurred editorial and advertising boundaries.
In response to regulatory concerns, Eucalyptus introduced phone-based GP consultations to replace asynchronous online forms. [2]
In June 2025, the TGA issued class-wide safety warnings for all GLP-1 and dual GIP/GLP-1 receptor agonists, including medications prescribed through Juniper, regarding aspiration risks during general anaesthesia. The warnings required updates to product information across all suppliers of these medications. [18]
In September 2025, media and professional bodies raised warnings about the use of artificial intelligence chatbots in telehealth weight-loss programs after one Eucalyptus-linked provider introduced an AI chatbot to handle the majority of user interactions, including advice on medication use and dietary questions. Experts cautioned that AI-driven coaching for sensitive areas such as weight management could pose risks if generic responses failed to account for individual medical or psychological conditions, and emphasised that safeguards and clear boundaries were needed to ensure human clinical oversight. Company representatives said the AI chatbot was strictly programmed with vetted clinical information and directed users to human clinicians when appropriate. [19]
In late December 2025, peak eating disorder advocacy groups expressed concern about the rapid rollout and marketing of GLP-1 weight-loss treatments prescribed via telehealth, warning that aggressive social media campaigns could target vulnerable individuals without sufficient medical monitoring. Media reports cited promotional activity, including a Black Friday sale by Juniper, and noted that the company referred to "pesky Aussie laws" as having prevented it from providing more information about the medication to potential customers. Representatives of Eucalyptus said promotions related only to the cost of accessing medical services and that clinical eligibility was determined through structured assessments, while advocacy groups called for stronger safeguards and closer regulatory oversight of advertising practices. [11]
{{cite web}}: |last= has generic name (help)